EN PL

FDA: Draft guidance: Analgesic Indications: Developing Drug and Biological Products

13.02.2014
This guidance focuses on clinical drug development and trial design issues and chemistry, manufacturing, and controls (CMC) concerns that are unique to the study of acute, chronic, and breakthrough pain and the labeling considerations for analgesic drugs.